O'Brien Carolyn R, Malik Richard, Globan Maria, Reppas George, McCowan Christina, Fyfe Janet A
1 Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, VIC 3030, Australia.
2 Centre for Veterinary Education, The University of Sydney, NSW 2006, Australia.
J Feline Med Surg. 2017 May;19(5):498-512. doi: 10.1177/1098612X17706467.
This paper, the first in a series of three on 'feline leprosy', provides a detailed description of disease referable to Candidatus 'Mycobacterium tarwinense', the most common cause of feline leprosy in Victoria, Australia.
Cases were sourced retrospectively and prospectively for this observational study, describing clinical, geographical and molecular microbiological data for cats definitively diagnosed with Candidatus 'M tarwinense' infection.
A total of 145 cases of feline leprosy were scrutinised; 114 'new' cases were sourced from the Victorian Infectious Diseases Reference Laboratory records, veterinary pathology laboratories or veterinarians, and 31 cases were derived from six published studies. Forty-two cats were definitively diagnosed with Candidatus 'M tarwinense' infection. Typically, cats were between 3 and 11 years of age, with no gender predilection, and were generally systemically well. All had outdoor access. Most cats underwent surgical resection of lesions with adjunctive medical therapy, often utilising a combination of oral clarithromycin and rifampicin for at least 3 months. Prognosis for recovery was generally good. Resolution of lesions was not observed in the absence of treatment, but a number of untreated cats continued to enjoy an acceptable quality of life despite persistence of the disease, which extended locally but did not appear to disseminate to internal organs. Preliminary results of draft genome sequencing confirmed that the species is a member of the Mycobacterium simiae complex.
Candidatus 'M tarwinense', a fastidious member of the M simiae complex, is capable of causing feline leprosy with a tendency to produce lesions on the head, particularly involving the eyes and periocular skin. The disease has an indolent clinical course and generally responds favourably to therapy despite lesions often containing large numbers of organisms. Detailed genomic analysis may yield clues as to the environmental niche and culture requirement of this elusive organism. Prospective treatment trials and/or drug susceptibility testing in specialised systems would further inform treatment recommendations.
本文是关于“猫类麻风病”的三篇系列文章中的第一篇,详细描述了由“塔温尼氏假结核分枝杆菌”引起的疾病,该菌是澳大利亚维多利亚州猫类麻风病最常见的病因。
通过回顾性和前瞻性研究收集病例,描述确诊感染“塔温尼氏假结核分枝杆菌”的猫的临床、地理和分子微生物学数据。
共审查了145例猫类麻风病病例;114例“新”病例来自维多利亚传染病参考实验室记录、兽医病理实验室或兽医,31例病例来自六项已发表的研究。42只猫被确诊感染“塔温尼氏假结核分枝杆菌”。通常,猫的年龄在3至11岁之间,无性别倾向,一般全身状况良好。所有猫都有户外活动机会。大多数猫接受了病变的手术切除并辅以药物治疗,通常使用口服克拉霉素和利福平联合治疗至少3个月。恢复预后总体良好。未经治疗则未观察到病变消退,但一些未经治疗的猫尽管疾病持续存在,仍能维持可接受的生活质量,疾病局限于局部扩展,但似乎未扩散至内脏器官。基因组测序草图的初步结果证实该菌种是猿分枝杆菌复合群的成员。
“塔温尼氏假结核分枝杆菌”是猿分枝杆菌复合群中的一种苛求菌,能够引起猫类麻风病,倾向于在头部产生病变,尤其是累及眼睛和眼周皮肤。该疾病临床病程缓慢,尽管病变通常含有大量病菌,但一般对治疗反应良好。详细的基因组分析可能会揭示这种难以捉摸的病菌的环境生态位和培养要求。在专门系统中进行前瞻性治疗试验和/或药敏试验将为治疗建议提供更多信息。